This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	c-Met proto-oncogene (MET; HGFR); dynamin (DNM); clathrin (CLT)	<i>In vitro</i> and mouse studies suggest inhibiting MET endocytosis could help treat cancer. In mouse fibroblasts expressing activating <i>Met</i> mutations, blocking endocytosis using a DNM inhibitor or Clt-targeted small hairpin RNA decreased cell migration and anchorage-independent cell growth compared with those seen using vehicle or shRNA control. In mice, topical treatment with a DNM inhibitor or Clt-targeted shRNA decreased the size of <i>Met</i> -mutant tumors compared with treatment using vehicle or shRNA control. Next steps include testing other models of MET-dependent tumorigenesis.	Findings unpatented; unavailable for licensing	Joffre, C. <i>et al. Nat. Cell Biol.</i> ; published online June 5, 2011; doi:10.1038/ncb2257 Contact: Stéphanie Kermorgant, Queen Mary, University of London, London, U.K. e-mail: s.kermorgant@qmul.ac.uk
SciBX 4(24); doi:10.1038/scibx.2011.680 Published online June 16, 2011				